Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948173 | 0.85 | IL4I1 (0.43) | IL4I1NPC1RAB9ASMN1; SMN2PDGFRB | |
| SCHEMBL15784441 | 0.82 | RAB9A (0.37) | IL4I1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL23805539 | 0.81 | CAMKK2 (0.38) | IL4I1NPC1RAB9ASMN1; SMN2PDGFRB | |
| SCHEMBL18532670 | 0.81 | PDGFRB (0.38) | IL4I1NPC1RAB9ASMN1; SMN2PDGFRB | |
| SCHEMBL27903531 | 0.81 | MAPK1 (0.42) | NPC1RAB9APDGFRBFLT3MAPK1 | |
| SCHEMBL2609391 | 0.81 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL11679493 | 0.80 | PTGS2 (0.47) | IL4I1LDHAHSD17B1HSD17B2CHRNA7 | |
| SCHEMBL24636033 | 0.80 | BCHE (0.47) | NPC1RAB9ASMN1; SMN2HSD17B1HSD17B2 | |
| SCHEMBL15784442 | 0.80 | CHRNA7 (0.34) | IL4I1HSD17B1HSD17B2CHRNA7ALOX5AP | |
| SCHEMBL1304066 | 0.80 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | IL4I1 53/4885NPC1 3297/4885RAB9A 688/4885 |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | IL4I1 3351/4885NPC1 3046/4885RAB9A 2377/4885 |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | IL4I1 778/4885NPC1 1238/4885RAB9A 2484/4885 |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | IL4I1 125/4885NPC1 1262/4885RAB9A 531/4885 |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | IL4I1 88/4885NPC1 2892/4885RAB9A 516/4885 |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | NPY5R, NPY1R, NPY4R | IL4I1 294/4885NPC1 1881/4885RAB9A 3413/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | IL4I1 1573/4885NPC1 2326/4885RAB9A 327/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | IL4I1 125/4885NPC1 1262/4885RAB9A 531/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | IL4I1 69/4885NPC1 3783/4885RAB9A 720/4885 |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | IL4I1 2646/4885NPC1 2169/4885RAB9A 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.